The 340B Drug Pricing Program, established over 30 years ago to afford low-income and uninsured patients discounted drugs, anticipates several significant circuit court decisions this year that may instigate considerable change. The United States Congress developed this program in 1992, enabling covered entities including qualifying safety-net hospitals, clinics, and other providers to purchase outpatient drugs at reduced prices from manufacturing companies associated with Medicaid, with the aim of neutralizing the impact of escalating drug costs. The program is termed after Section 340B of the Public Health Service Act with discounts ranging from 25% to 50%, thereby enabling providers to offer uninsured and underinsured patients these services.
As this year unfurls, various cases concerning the distribution of drugs will move forward, while the various states grapple with the task of legislating to bridge the existing gaps in this program. In light of these impending circuit court decisions, legal professionals, particularly those in healthcare and pharmaceutical industries, need to be abreast of changes while also preparing for different probable outcomes. Although the exact scope and implications lie in the realm of future unfolding, the anticipated alteration in the landscape of this program is certain.
The forthcoming decisions and legislative measures will likely stir the proverbial waters of the healthcare and pharmaceutical industries. A close eye should be kept on these developments, as well as any potential impact on not only service providers and patients, but also on larger industry trends and standards. The decisions could also potentially impact state-level health programs and policies.
This story is still developing and more details will be reported as they become available.
For the original article and more updates, visit Bloomberg Law.